Loading
Prostate Cancer Treatment and Research · Journal article
Frontiers in Pharmacology · September 7, 2026
A consensus or society position rather than new primary data.
This is a narrative review of Lu-177 radiopharmaceutical therapy in oncology that evaluates the current clinical evidence landscape and identifies key barriers to broader adoption. The authors conclude that whilst regulatory approvals exist for neuroendocrine tumours and metastatic castration-resistant prostate cancer, the evidence base is limited by small non-randomised studies, heterogeneous trial design, and insufficient standardisation of dosimetry and biomarkers, necessitating a strategic roadmap toward evidence-based personalisation.
Narrative review. Patients treated with or eligible for Lu-177 radiopharmaceutical therapy across selected malignancies.. Intervention: Lu-177–based Radioligand Therapy (RLT), including Lutathera® and Pluvicto®..
Lu-177 RLT has regulatory approval for neuroendocrine tumours (Lutathera®) and metastatic castration-resistant prostate cancer (Pluvicto®) Much existing evidence derives from small, non-randomised studies with inherent risk of bias Key limitations include lack of standardised and clinically actionable dosimetry, insufficient predictive biomarkers beyond target expression, and vulnerability of isotope supply chains
No specific efficacy or safety data points extracted from primary trials Long-term safety data stated as limited but not quantified
Clinicians should recognise that whilst Lu-177 RLT has established regulatory approval in two malignancy settings, the evidence base remains limited by methodological constraints, and broader clinical translation requires standardisation of dosimetry, biomarker development, and more rigorous trial design. This review provides a framework for advancing the field toward personalised, evidence-based implementation rather than empiric application.
A narrative review synthesizing clinical trial evidence, regulatory approvals, and translational findings to propose a strategic framework for advancing Lu-177 radiopharmaceutical therapy, rather than reporting a primary empirical result.
As stated by the source record.
Clinicians should recognise that whilst Lu-177 RLT has established regulatory approval in two malignancy settings, the evidence base remains limited by methodological constraints, and broader clinical translation requires standardisation of dosimetry, biomarker development, and more rigorous trial design. This review provides a framework for advancing the field toward personalised, evidence-based implementation rather than empiric application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lutetium-177 ( 177 Lu)–based Radioligand Therapy (RLT) has emerged as an important modality in precision oncology, with demonstrated clinical benefit in selected malignancies. Its clinical relevance is underscored by regulatory approvals of Lutathera® for neuroendocrine tumours and Pluvicto® for metastatic castration-resistant prostate cancer. However, despite these advances, the field faces significant challenges that limit broader clinical translation and optimisation. In this review, we provide a critical and balanced evaluation of the current 177 Lu RLT landscape, integrating evidence from clinical trials, emerging targets, and translational studies. We highlight that much of the existing evidence is derived from small, non-randomised studies with inherent risk of bias, limiting the strength of clinical conclusions. Key challenges include the lack of standardised and clinically actionable dosimetry, insufficient predictive biomarkers beyond target expression, vulnerability of isotope supply chains, and the development of drug-evasive traits in malignant cells. In addition, heterogeneity in trial design and limited long-term safety data further constrain clinical implementation. We propose a strategic roadmap to advance 177 Lu RLT toward a more rigorous, reproducible, and equitable precision oncology framework, emphasising the transition from empiric application to evidence-based personalisation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.